| I-07 Dominik Lott Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate Wednesday 10:30-12:00 |
| I-52 Sebastian Polak Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment. Wednesday 10:30-12:00 |
| II-06 Bernard Sebastien Pharmacokinetic/Pharmacodynamic Modelling of Recurrent Adverse Events as Function of Drug Concentration and Time Wednesday 15:10-16:30 |
| II-30 Mirjam Trame Translational in-vitro in-vivo model to correlate HIPS derived cardiomyocyte contractility assay and in-vivo dog telemetry based dPdtmax measurements Wednesday 15:10-16:30 |
| II-35 Zofia Tylutki Simulation of pharmacokinetics of amitriptyline and nortriptyline and their common effect on human cardiac electrophysiology in healthy population Wednesday 15:10-16:30 |
| II-70 Jochen Zisowsky Simulation Study on a Method for PK-QT Analyses When Several Active Compounds or Metabolites Are Present Wednesday 15:10-16:30 |
| III-58 Pavel Kovalenko Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration Thursday 09:50-11:20 |
